GenMark Diagnostics CEO Hany Massarany Unloads 1,115 Shares (GNMK)
GenMark Diagnostics (NASDAQ:GNMK) CEO Hany Massarany sold 1,115 shares of GenMark Diagnostics stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.64, for a total value of $12,978.60. Following the completion of the transaction, the chief executive officer now directly owns 185,583 shares in the company, valued at approximately $2,160,186. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $16.00 price target on the stock, down previously from $17.00. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $15.00 price target on the stock, down previously from $16.00. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $15.00.
GenMark Diagnostics (NASDAQ:GNMK) traded down 0.08% on Friday, hitting $11.99. 129,901 shares of the company’s stock traded hands. GenMark Diagnostics has a 52-week low of $8.48 and a 52-week high of $14.18. The stock has a 50-day moving average of $9.90 and a 200-day moving average of $11.36. The company’s market cap is $498.9 million.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.04. The company had revenue of $7.91 million for the quarter, compared to the consensus estimate of $6.40 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was down 28.7% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-1.15 EPS for the current fiscal year.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.